Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) Short Interest Down 60.6% in June

Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) saw a large drop in short interest in June. As of June 30th, there was short interest totaling 4,645 shares, a drop of 60.6% from the June 15th total of 11,804 shares. Currently, 0.0% of the company’s stock are short sold. Based on an average daily volume of 6,542 shares, the short-interest ratio is presently 0.7 days.

Inhibitor Therapeutics Stock Performance

Shares of Inhibitor Therapeutics stock remained flat at $0.08 on Wednesday. The stock had a trading volume of 184 shares, compared to its average volume of 3,021. Inhibitor Therapeutics has a 1-year low of $0.04 and a 1-year high of $0.12. The company has a market capitalization of $13.12 million, a P/E ratio of -7.55 and a beta of -0.78. The stock’s fifty day moving average is $0.08 and its 200 day moving average is $0.08.

Inhibitor Therapeutics Company Profile

Inhibitor Therapeutics, Inc, a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. It has license agreement with Johns Hopkins University. The company was formerly known as HedgePath Pharmaceuticals, Inc and changed its name to Inhibitor Therapeutics, Inc in August 2019.